Study to Measure the Efficacy and Safety of Abrocitinib (PF-04965842) in Subjects Aged 12 Years And Older, With Moderate to Severe Atopic Dermatitis
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of PF-04965842 Monotherapy in Subjects Aged 12 Years and Older, With Moderate to Severe Atopic Dermatitis (JADE Mono-2)
Category & Conditions: Skin Diseases and Conditions
Medicine: abrocitinib (PF-04965842)
ClinicalTrials.gov Identifier (NCT): NCT03575871
Protocol ID: B7451013
PrintDownloadOpen Plain Language Summary Result: Click here